Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T cell infiltration

PURPOSE: A phase I study was conducted to determine safety, clinical efficacy, and anti-tumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral (IT) administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expre...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Lee, Jay M., Lee, Mi-Heon, Garon, Edward B., Goldman, Jonathan W., Salehi-Rad, Ramin, Baratelli, Felicita E., Schaue, Dörthe, Wang, Gerald, Rosen, Fran, Yanagawa, Jane, Walser, Tonya C., Lin, Ying, Park, Stacy J., Adams, Sharon, Marincola, Francesco M., Tumeh, Paul C., Abtin, Fereidoun, Suh, Robert, Reckamp, Karen L., Lee, Gina, Wallace, William D., Lee, Sarah, Zeng, Gang, Elashoff, David A., Sharma, Sherven, Dubinett, Steven M.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599263/
https://ncbi.nlm.nih.gov/pubmed/28468947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2821
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים